488 related articles for article (PubMed ID: 34435935)
21. Pityriasis rosea-like drug eruption due to bupropion: a case report.
Polat M; Uzun Ö; Örs I; Boran Ç
Hum Exp Toxicol; 2014 Dec; 33(12):1294-6. PubMed ID: 24700110
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.
Avallone G; Quaglino P; Cavallo F; Roccuzzo G; Ribero S; Zalaudek I; Conforti C
Int J Dermatol; 2022 Oct; 61(10):1187-1204. PubMed ID: 35141881
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
[TBL] [Abstract][Full Text] [Related]
24. Pityriasis rosea following SARS-CoV-2 vaccination: A case series.
Temiz SA; Abdelmaksoud A; Dursun R; Durmaz K; Sadoughifar R; Hasan A
J Cosmet Dermatol; 2021 Oct; 20(10):3080-3084. PubMed ID: 34363731
[No Abstract] [Full Text] [Related]
25. Recurrent pityriasis rosea: A case report.
Li A; Li P; Li Y; Li W
Hum Vaccin Immunother; 2018 Apr; 14(4):1024-1026. PubMed ID: 29182459
[TBL] [Abstract][Full Text] [Related]
26. Pityriasis following COVID-19 vaccinations: a systematic review.
Duzett L; Mercado G; Tasouli-Drakou V; Kane A; Tam A
Dermatol Reports; 2024 Mar; 16(1):9742. PubMed ID: 38623364
[TBL] [Abstract][Full Text] [Related]
27. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19.
Dormann H; Grummt S; Karg M
Dtsch Arztebl Int; 2021 Jun; 118(25):431. PubMed ID: 34374333
[No Abstract] [Full Text] [Related]
28. Pityriasis Rosea: An Updated Review.
Leung AKC; Lam JM; Leong KF; Hon KL
Curr Pediatr Rev; 2021; 17(3):201-211. PubMed ID: 32964824
[TBL] [Abstract][Full Text] [Related]
29. Impact of COVID-19 on Clinicopathological Spectrum of Pityriasis Rosea in Korea.
Kim DH; Cho JH; Park SJ; Seo SH; Ahn HH
J Korean Med Sci; 2022 Jun; 37(24):e190. PubMed ID: 35726143
[TBL] [Abstract][Full Text] [Related]
30. Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine.
Huang L; Yao Z; Zhang J
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e9-e11. PubMed ID: 34492136
[No Abstract] [Full Text] [Related]
31. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination.
Shin SH; Hong JK; Hong SA; Li K; Yoo KH
Int J Infect Dis; 2022 Jan; 114():88-89. PubMed ID: 34740803
[No Abstract] [Full Text] [Related]
32. Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature.
Veraldi S; Boneschi V; Cusini M; Maronese CA
Dermatol Reports; 2023 Mar; 15(1):9503. PubMed ID: 37063394
[TBL] [Abstract][Full Text] [Related]
33. Molecular study of recent virus and its relationship to Pityriasis rosea.
Kawen AA
J Popul Ther Clin Pharmacol; 2022; 29(1):e109-e115. PubMed ID: 35686902
[TBL] [Abstract][Full Text] [Related]
34. Pityriasis rosea.
Stulberg DL; Wolfrey J
Am Fam Physician; 2004 Jan; 69(1):87-91. PubMed ID: 14727822
[TBL] [Abstract][Full Text] [Related]
35. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
37. Pityriasis rosea after mRNA COVID-19 vaccination.
Abdullah L; Hasbani D; Kurban M; Abbas O
Int J Dermatol; 2021 Sep; 60(9):1150-1151. PubMed ID: 34110010
[No Abstract] [Full Text] [Related]
38. Pityriasis Rosea Induced by COVID-19 Vaccination.
Khattab E; Christaki E; Pitsios C
Eur J Case Rep Intern Med; 2022; 9(2):003164. PubMed ID: 35265550
[TBL] [Abstract][Full Text] [Related]
39. Palmar herald patch in pityriasis rosea.
Polat M; Yildirim Y; Makara A
Australas J Dermatol; 2012 Aug; 53(3):e64-5. PubMed ID: 22881477
[TBL] [Abstract][Full Text] [Related]
40. Unilateral pityriasis rosea in a child: A rare clinical presentation.
Oğrum A
Turk J Pediatr; 2017; 59(2):214-216. PubMed ID: 29276879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
